Article

Alcon third-quarter profit increases by 51%

Alcon's quarterly earnings per share came in above analysts' expectations and rose 51% from last year.

Hunenberg, Switzerland-Alcon's quarterly earnings per share came in above analysts' expectations and rose 51% from last year. The company also lowered its revenue guidance, while raising its earnings outlook for the full year 2008.

The reported net income for the third quarter was $627.1 million or $2.07 per share, higher than last year's $415.3 million or $1.38 per share for the third quarter, said the company in a prepared statement. The net earnings for the most recent quarter included a $239.5 million tax benefit associated with losses on the value of the company's investment in and advances to the former Summit Autonomous Inc.

Sales for the quarter rose 14.1% to $1.52 billion from $1.34 billion in the prior-year quarter, while analysts had a revenue consensus of $1.54 billion, according to the company. The acquisition of WaveLight AG contributed 1.4 percentage points of sales growth in the third quarter.

Consumer eye-care sales for the quarter increased 10.5% to $223.7 million. Sales of contact lens disinfectants grew 2.6% and sales of artificial tears products increased 28%, said the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.